JP2003511396A5 - - Google Patents

Download PDF

Info

Publication number
JP2003511396A5
JP2003511396A5 JP2001529267A JP2001529267A JP2003511396A5 JP 2003511396 A5 JP2003511396 A5 JP 2003511396A5 JP 2001529267 A JP2001529267 A JP 2001529267A JP 2001529267 A JP2001529267 A JP 2001529267A JP 2003511396 A5 JP2003511396 A5 JP 2003511396A5
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
pharmaceutical composition
formula
composition according
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001529267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003511396A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/027612 external-priority patent/WO2001026467A1/en
Publication of JP2003511396A publication Critical patent/JP2003511396A/ja
Publication of JP2003511396A5 publication Critical patent/JP2003511396A5/ja
Pending legal-status Critical Current

Links

JP2001529267A 1999-10-08 2000-10-06 化学療法を増強する方法 Pending JP2003511396A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15832299P 1999-10-08 1999-10-08
US60/158,322 1999-10-08
PCT/US2000/027612 WO2001026467A1 (en) 1999-10-08 2000-10-06 Methods of enhancing chemotherapy

Publications (2)

Publication Number Publication Date
JP2003511396A JP2003511396A (ja) 2003-03-25
JP2003511396A5 true JP2003511396A5 (https=) 2006-01-05

Family

ID=22567591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001529267A Pending JP2003511396A (ja) 1999-10-08 2000-10-06 化学療法を増強する方法

Country Status (7)

Country Link
EP (2) EP2064951A1 (https=)
JP (1) JP2003511396A (https=)
AT (1) ATE426335T1 (https=)
AU (1) AU782401B2 (https=)
CA (1) CA2382727A1 (https=)
DE (1) DE60041880D1 (https=)
WO (1) WO2001026467A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084543A1 (en) 2002-04-10 2003-10-16 Virginia Commonwealth University Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
AU2003257329C1 (en) 2002-08-19 2010-07-22 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
AU2006250809B2 (en) 2005-05-25 2011-05-12 Lorus Therapeutics Inc. 2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer
EP2454943B1 (en) 2010-11-23 2020-05-27 GEA Food Solutions Bakel B.V. Apparatus and method for the production of a product with an interleaver
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
ES2775579T3 (es) 2013-10-04 2020-07-27 Aptose Biosciences Inc Composiciones para el tratamiento del cáncer
LU100887B1 (en) 2017-02-24 2018-12-18 Bioactor B V Compounds and compositions against visceral hypersensitivity
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors
WO2025119974A1 (en) 2023-12-04 2025-06-12 Bioactor Bv Naringin or naringenin for improving sleep quality

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
US5756527A (en) * 1995-06-07 1998-05-26 Ontogen Corporation Imidazole derivatives useful as modulators of multi drug resistances
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators

Similar Documents

Publication Publication Date Title
RU2470016C2 (ru) Производное бипиразола
JP2005515966A5 (https=)
JP2004505052A5 (https=)
WO2004043389B1 (en) Methods of treating cancer and related methods
JP2007507538A5 (https=)
ES2089027T3 (es) Forma de dosificacion transmucosica.
JP2009102342A5 (https=)
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
WO2011040894A1 (en) Topical compositions of opioid antagonists and methods for treating skin conditions therewith
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2003511396A5 (https=)
JP2006512324A5 (https=)
JP2011500781A5 (https=)
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
ATE398441T1 (de) Octenidinhaltige lutschtabletten gegen entzündliche erkrankungen des mund- und rachenraums
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
US8293787B2 (en) Gallium compositions for the treatment of liver cancer and methods of use
JP2006514681A5 (https=)
RU2018130097A (ru) Лечение экземы кистей
RU2016110546A (ru) Комбинированная лекарственная терапия
JP2017514829A5 (https=)
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
JPH0840903A (ja) 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物